IL12B
ENSG00000113302
Target class
Secreted protein
Chromosome
5
Approved drugs
5
Clinical candidates (approved and in development)
8
- Approved drugs
- 5
- Clinical candidates (approved and in development)
- 8
- Chemical probe available
- No
- Target name
- IL12B
- Gene name
- Interleukin 12B
- Gene symbol
- IL12B
- Previous gene symbols
- NKSF2
- Protein name
- Interleukin-12 subunit beta (IL-12B) (Cytotoxic lymphocyte maturation factor 40 kDa subunit) (CLMF p40) (IL-12 subunit p40) (NK cell stimulatory factor chain 2) (NKSF2)
- CLMF
- IL-12B
- NKSF
- CLMF2
- Gene biotype
- Protein coding
- Gene family
- Immunoglobulin like domain containing|Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1
- Tissue specificity (Gini)
- 0.859
- Tissue specificity (tau)
- 0.964
- KEGG gene identifiers
- hsa:3593
- Protein interaction confidence
- 0.803619
- Protein interaction partners
- 21
- R-HSA-6783783
- R-HSA-6785807
- R-HSA-9020591
- R-HSA-9020933
- End position
- 159330863
- Start position
- 159314780
- Chromosome
- 5
- Strand
- Reverse
- Secreted.
- Tissue specificity (tau)
- 0.963585
- Expression inequality (Gini)
- 0.858994
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 1
- Pituitary
- 0.77
- Testis
- 0.14
- Kidney - Cortex
- 0.14
- Minor Salivary Gland
- 0.14
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes1
- Pituitary0.77
- Testis0.14
- Kidney - Cortex0.14
- Minor Salivary Gland0.14
- Lung0.12
- Spleen0.1
- Kidney - Medulla0.08
- Brain - Cerebellum0.07
- Brain - Cerebellar Hemisphere0.06
- Thyroid0.04
- Cervix - Endocervix0.04
- Small Intestine - Terminal Ileum0.04
- Cells - Cultured fibroblasts0.02
- Brain - Nucleus accumbens (basal ganglia)0.02
- Brain - Hypothalamus0.02
- Skin - Sun Exposed (Lower leg)0.02
- Esophagus - Mucosa0.02
- Whole Blood0.01
- Skin - Not Sun Exposed (Suprapubic)0.01
- Brain - Putamen (basal ganglia)0.01
- Brain - Caudate (basal ganglia)0.01
- Brain - Frontal Cortex (BA9)0.01
- Brain - Substantia nigra0.01
- Brain - Anterior cingulate cortex (BA24)0.01
And 29 more, listed on the interactive page.
- GO:0001817
- GO:0002230
- GO:0002827
- GO:0002860
- GO:0007259
- GO:0010224
- GO:0016477
- GO:0030101
- GO:0032693
- GO:0032700
- GO:0032725
- GO:0032729
- GO:0032733
- GO:0032735
- GO:0032740
- GO:0032760
- GO:0032816
- GO:0032819
- GO:0032946
- GO:0034105
- GO:0034393
- GO:0035722
- GO:0038155
- GO:0042088
- GO:0042093
And 15 more, listed on the interactive page.
- GO:0005576
- GO:0005788
- GO:0005829
- GO:0031906
- GO:0043514
- GO:0070743
- GO:0005125
- GO:0005143
- GO:0005515
- GO:0008083
- GO:0042164
- GO:0042802
- GO:0045519
- GO:0046982
Related records
Trials (501)
- A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants
- A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
- A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis
- A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis
- A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
- A Long-term Extension Study of Ustekinumab in Pediatric Participants
- A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial to Assess the Efficacy and Safety of Ustekinumab in Association With Prednisone for the Treatment of Non-infectious Severe Uveitis (NISU)
- A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
- A Multicentered Prospective Cohort Study of Chinese IBD Patients
- A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers
- A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations
- A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Drugs (8)
- Brazikumab Interleukin-23 inhibitor
- Briakinumab Interleukin-23 inhibitor
- Ebdarokimab Interleukin-12 inhibitor
- Guselkumab Interleukin-23 inhibitor
- Mirikizumab Interleukin-23 inhibitor
- Risankizumab Interleukin-23 inhibitor
- Tildrakizumab Interleukin-23 inhibitor
- Ustekinumab Interleukin-12 inhibitor